Editas Medicine, Inc. (EDIT)
$2.44-11.27%Close
BUYCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $239M
- Beta
- 2.00
- P/E (TTM)
- -3.27
- Short % float
- 37.97%
- Days to cover
- 9.3
- SI change
- +23.9%
- 1W
- -10.62%
- 1M
- -10.95%
- vs SPY 1W
- -11.04%
- vs SPY 1M
- -13.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on EDIT?
- LOPJLB’s latest quantitative signal on Editas Medicine, Inc. (EDIT) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is EDIT in?
- Editas Medicine, Inc. (EDIT) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Editas Medicine, Inc. (EDIT) do?
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. T…